Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Read More…
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone574-267-6131
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.93 billion
Profitability
Miscellaneous
Employees19,000
Next Earnings Date10/25/2019 (Estimated)
OptionableOptionable
Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions
What is Zimmer Biomet's stock symbol?
Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."
How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?
Zimmer Biomet announced a quarterly dividend on Tuesday, June 11th. Stockholders of record on Friday, June 28th will be given a dividend of $0.24 per share on Wednesday, July 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.72%. The ex-dividend date is Thursday, June 27th. View Zimmer Biomet's Dividend History.
How were Zimmer Biomet's earnings last quarter?
Zimmer Biomet Holdings Inc (NYSE:ZBH) released its earnings results on Friday, July, 26th. The medical equipment provider reported $1.93 EPS for the quarter, beating analysts' consensus estimates of $1.91 by $0.02. The medical equipment provider earned $1.99 billion during the quarter, compared to analysts' expectations of $1.98 billion. Zimmer Biomet had a negative net margin of 4.56% and a positive return on equity of 13.40%. Zimmer Biomet's revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.92 EPS. View Zimmer Biomet's Earnings History.
When is Zimmer Biomet's next earnings date?
What guidance has Zimmer Biomet issued on next quarter's earnings?
Zimmer Biomet updated its FY19 earnings guidance on Friday, July, 26th. The company provided earnings per share (EPS) guidance of $7.75 -7.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.80. The company issued revenue guidance of $7.94 billion, compared to the consensus revenue estimate of prior $7.70-7.90.
What price target have analysts set for ZBH?
22 brokerages have issued twelve-month price targets for Zimmer Biomet's stock. Their forecasts range from $108.00 to $167.00. On average, they anticipate Zimmer Biomet's share price to reach $141.5576 in the next year. This suggests a possible upside of 5.9% from the stock's current price. View Analyst Price Targets for Zimmer Biomet.
What is the consensus analysts' recommendation for Zimmer Biomet?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 1 sell rating, 6 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zimmer Biomet.
What are Wall Street analysts saying about Zimmer Biomet stock?
Here are some recent quotes from research analysts about Zimmer Biomet stock:
- 1. According to Zacks Investment Research, "We believe escalating costs and expenses are denting the adjusted operating margin for Zimmer Biomet. Adverse currency movements continue to be a concern. Declining dental sales at CER also disappoint. On a positive note, the company witnessed strength in the Asia Pacific and EMEA regions as well as in the Spine & CMF business. Supported by focus on priority areas like quality remediation, supply recovery efforts and product launches, the company has again reported strong top-line numbers for its S.E.T segment. We are also upbeat about the company’s receipt of FDA 510(k) for the ROSA Knee System. Zimmer Biomet has outperformed its industry in the past six months." (4/13/2019)
- 2. BTIG Research analysts commented, "an easy comp led us to believe that 3Q results were beatable. While top-line fell in-line with the Street and EPS was 3 cents higher (which would have satisfied investors in our view), sentiment was hampered by commentary related to FY19 (specifically ongoing margin pressures and lost sales from ZBH’s distribution agreement with BONESUPPORT (BONEX-OM, Not Rated)). Underlying rev. growth of 2.0% Y/Y improved Y/Y (helped by 3Q tenders, ~40bps by our est.) and while GMs were soft (as expected in 3Q), mgmt. commentary indicates ongoing margin pressure into FY19 along with increasing Fx headwinds. Collectively headwinds will lower EPS by $0.15 in FY19, offset by a lower interest expense and tax rate." (10/28/2018)
- 3. Needham & Company LLC analysts commented, "In an 8-K filed this morning, ZBH disclosed that it received a FDA warning letter late Friday, 8/24.The warning letter isn’t a surprise in our view given ZBH’s previous two Form 483s. While we think that the risk of a consent decree has probably increased, we still think it is very unlikely given ZBH’s significant efforts and investments in addressing the Biomet plant issues. We don’t expect any impact to ZBH’s financial results from the warning letter and maintain our Buy rating." (8/27/2018)
- 4. Cantor Fitzgerald analysts commented, "We rate ZBH shares Overweight and have a 12-month price target of $150. ZBH has started a new era with recently hired the CEO of 10 years resigned in July. Under the new CEO near-term challenges persist, but we would expect the company to benefit from Hanson’s broader medtech background. ZBH is the least expensive large-cap medtech stock on a P/E basis, currently trading at a discount to the S&P. We believe the risk/reward is attractive at these levels and think there could be significant upside to shares if ZBH posts a couple of quarters of accelerating growth." (8/27/2018)
Has Zimmer Biomet been receiving favorable news coverage?
Media stories about ZBH stock have been trending positive recently, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zimmer Biomet earned a coverage optimism score of 2.5 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term. View News Stories for Zimmer Biomet.
Who are some of Zimmer Biomet's key competitors?
Some companies that are related to Zimmer Biomet include Intuitive Surgical (ISRG), Edwards Lifesciences (EW), COLOPLAST A/S/ADR (CLPBY), Smith & Nephew (SNN), Align Technology (ALGN), Steris (STE), DEMANT A S/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Avanos Medical (AVNS), Inogen (INGN), Establishment Labs (ESTA), Sientra (SIEN), RTI Surgical (RTIX) and Invacare (IVC).
What other stocks do shareholders of Zimmer Biomet own?
Who are Zimmer Biomet's key executives?
Zimmer Biomet's management team includes the folowing people:
- Mr. Bryan C. Hanson, Pres, CEO & Director (Age 52)
- Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 55)
- Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 47)
- Mr. Sang Yi, Pres of Asia Pacific (Age 57)
- Mr. Ivan Tornos, Group Pres of Orthopedics (Age 43)
Who are Zimmer Biomet's major shareholders?
Zimmer Biomet's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.00%), BlackRock Inc. (8.00%), Vanguard Group Inc. (7.53%), JPMorgan Chase & Co. (4.78%), Invesco Ltd. (3.45%) and Price T Rowe Associates Inc. MD (2.95%). Company insiders that own Zimmer Biomet stock include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Chad F Phipps, Katarzyna Mazur-Hofsaess, Michael J Farrell, Michael W Michelson, Sang Yi, Syed A Jafry and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet.
Which institutional investors are selling Zimmer Biomet stock?
ZBH stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Balyasny Asset Management LLC, First Trust Advisors LP, UBS Asset Management Americas Inc., Jennison Associates LLC, Jennison Associates LLC, Zurich Insurance Group Ltd FI and Bank of New York Mellon Corp. Company insiders that have sold Zimmer Biomet company stock in the last year include Chad F Phipps and Sang Yi. View Insider Buying and Selling for Zimmer Biomet.
Which institutional investors are buying Zimmer Biomet stock?
ZBH stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Invesco Ltd., Point72 Asset Management L.P., Prudential Financial Inc., Suvretta Capital Management LLC, Waddell & Reed Financial Inc., D. E. Shaw & Co. Inc. and Man Group plc. Company insiders that have bought Zimmer Biomet stock in the last two years include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Michael J Farrell, Michael W Michelson and Syed A Jafry. View Insider Buying and Selling for Zimmer Biomet.
How do I buy shares of Zimmer Biomet?
Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zimmer Biomet's stock price today?
One share of ZBH stock can currently be purchased for approximately $133.64.
How big of a company is Zimmer Biomet?
Zimmer Biomet has a market capitalization of $27.44 billion and generates $7.93 billion in revenue each year. The medical equipment provider earns $-379,200,000.00 in net income (profit) each year or $7.64 on an earnings per share basis. Zimmer Biomet employs 19,000 workers across the globe.View Additional Information About Zimmer Biomet.
What is Zimmer Biomet's official website?
How can I contact Zimmer Biomet?
Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]
MarketBeat Community Rating for Zimmer Biomet (NYSE ZBH)
MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote "Outperform" if you believe ZBH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZBH will underperform the S&P 500 over the long term. You may vote once every thirty days.
